SCHEMBL5037952

SCHEMBL5037952

COC(C(=O)NCc1ccc(C#N)cc1)c1c(F)cc(Br)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.43
SLC1A2 P43004 2/20 0.41
SLC1A3 P43003 1/20 0.41
EPHX2 P34913 1/20 0.40
SCN5A Q14524 1/20 0.39
SCN9A Q15858 1/20 0.39
HIF1A Q16665 1/20 0.39
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.38
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.37
CTSD P07339 1/20 0.37
AKR1B1 P15121 1/20 0.36
KDM1A O60341 1/20 0.36
HDAC1 Q13547 1/20 0.36
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
PPARA Q07869 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5037955 1.00 PKM (0.43) PKMSLC1A2SLC1A3EPHX2SCN5A
SCHEMBL5045523 0.89 SLC1A2 (0.39) SLC1A2SLC1A3EPHX2SCN5ASCN9A
SCHEMBL5045525 0.89 SLC1A2 (0.39) SLC1A2SLC1A3EPHX2SCN5ASCN9A
SCHEMBL5041197 0.89 PKM (0.43) PKMEPHX2HIF1AALDH1A1L3MBTL1
SCHEMBL5041193 0.89 PKM (0.43) PKMEPHX2HIF1AALDH1A1L3MBTL1
SCHEMBL5041550 0.87 PKM (0.48) PKMSLC1A2SLC1A3EPHX2SCN5A
SCHEMBL5041552 0.87 PKM (0.48) PKMSLC1A2SLC1A3EPHX2SCN5A
SCHEMBL5037989 0.87 L3MBTL1 (0.42) PKMSLC1A2SLC1A3EPHX2SCN5A
SCHEMBL5045553 0.87 L3MBTL1 (0.42) PKMSLC1A2SLC1A3EPHX2SCN5A
SCHEMBL5040804 0.86 PKM (0.48) PKMSLC1A2SLC1A3EPHX2SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 PKM 4225/4885SLC1A2 2127/4885SLC1A3 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.